Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma

A 71-year-old woman with recurring stage IV hepatocellular carcinoma (HCC) was admitted to our hospital while being treated with atezolizumab and bevacizumab and complained of fatigue, vomiting, and appetite loss. The following were noted on admission: serum glucose level, 633 mg/dL; metabolic acide...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Munehiro, Tamada, Takashi, Takebayashi, Risa, Okuno, Gaku, Yagura, Iori, Nakamori, Shohei, Matsumura, Taishiro, Yoshioka, Takuto, Kaneko, Shizuka, Kanda, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332974/
https://www.ncbi.nlm.nih.gov/pubmed/36288990
http://dx.doi.org/10.2169/internalmedicine.0860-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332974/
https://www.ncbi.nlm.nih.gov/pubmed/36288990
http://dx.doi.org/10.2169/internalmedicine.0860-22

Ejemplares similares